Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTVNASDAQ:CELUNASDAQ:CLNNNASDAQ:IMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$1.57-1.9%$2.06$1.55▼$17.31$38.98MN/A172,555 shs193,560 shsCELUCelularity$1.91+1.6%$1.88$1.00▼$5.22$45.03M0.77337,800 shs69,222 shsCLNNClene$3.92-4.4%$3.32$2.28▼$7.59$36.83M0.4990,038 shs56,533 shsIMRNIMMURON$1.85-7.5%$5.04$1.50▼$2.87$10.94M0.9614,157 shs12,391 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-1.88%-6.55%-20.30%-50.32%+156,999,900.00%CELUCelularity+1.60%+6.70%-19.75%+7.73%-35.69%CLNNClene-4.39%-10.30%+49.62%+21.74%-44.18%IMRNIMMURON-1.60%+5.71%-4.15%0.00%-26.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics2.768 of 5 stars3.50.00.00.02.61.71.3CELUCelularity0.4098 of 5 stars0.02.00.00.02.71.70.0CLNNClene3.2191 of 5 stars3.63.00.00.03.32.50.6IMRNIMMURON1.331 of 5 stars3.53.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$17.801,033.76% UpsideCELUCelularity 0.00N/AN/AN/ACLNNClene 3.17Buy$40.00920.41% UpsideIMRNIMMURON 3.00Buy$5.00170.27% UpsideCurrent Analyst Ratings BreakdownLatest IMRN, CELU, ARTV, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/15/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.005/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/8/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K152.98N/AN/A$7.68 per share0.20CELUCelularity$54.22M0.84N/AN/A$0.37 per share5.16CLNNClene$340K103.53N/AN/A($1.06) per share-3.70IMRNIMMURON$3.21M3.37N/AN/A$1.46 per share1.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%8/7/2025 (Estimated)CELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/28/2025 (Estimated)CLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%-1,106.30%-105.11%8/6/2025 (Estimated)IMRNIMMURON-$4.55MN/A0.00N/AN/AN/AN/AN/AN/ALatest IMRN, CELU, ARTV, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/A5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AIMRNIMMURONN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.9313.93CELUCelularity4.070.380.28CLNNCleneN/A1.361.36IMRNIMMURONN/A6.805.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/ACELUCelularity19.02%CLNNClene23.28%IMRNIMMURON0.12%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%CELUCelularity22.10%CLNNClene35.30%IMRNIMMURON7.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 million19.15 millionN/ACELUCelularity22023.95 million18.66 millionOptionableCLNNClene1008.98 million5.81 millionOptionableIMRNIMMURONN/A5.85 million5.44 millionNot OptionableIMRN, CELU, ARTV, and CLNN HeadlinesRecent News About These CompaniesImmuron Limited American Depositary Shares (IMRN)June 10, 2025 | nasdaq.comImmuron Limited Issues New Shares in Compliance with Corporations ActJune 3, 2025 | tipranks.comImmuron Limited Reports Strong Sales Projections and Updates on Clinical Trials and Product LaunchesMay 30, 2025 | quiverquant.comQImmuron Letter to Shareholders: Projects UpdateMay 30, 2025 | globenewswire.comImmuron Limited Poised for Record Sales and Clinical AdvancementsMay 29, 2025 | tipranks.comImmuron Limited Issues New Shares in Compliance with Corporations ActMay 29, 2025 | tipranks.comCitizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial FailsMay 29, 2025 | msn.comImmuron Limited Announces Proposed Securities IssueMay 29, 2025 | tipranks.comIs Immuron Limited (IMRN) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comImmuron reports record Travelan salesApril 12, 2025 | uk.investing.comImmuron Limited Announces New Share IssuanceApril 11, 2025 | tipranks.comImmuron Limited Announces New Securities IssuanceApril 11, 2025 | tipranks.comImmuron Limited Announces Cessation of Performance RightsApril 11, 2025 | tipranks.comImmuron Travelan® highest sales in historyApril 10, 2025 | globenewswire.comImmuron Achieves Record Sales, Driven by Travelan®April 10, 2025 | sharecafe.com.auSImmuron Limited Achieves Record Sales with Travelan®April 9, 2025 | tipranks.comImmuron partners with Calmino to distribute ProIBS in Australia, New ZealandMarch 6, 2025 | markets.businessinsider.comImmuron Limited Announces Exclusive Distribution Agreement for ProIBS® in Australia and New ZealandMarch 5, 2025 | quiverquant.comQImmuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)March 5, 2025 | globenewswire.comImmuron Partners with Calmino to Launch IBS Treatment in Australia and New ZealandMarch 4, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRN, CELU, ARTV, and CLNN Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$1.57 -0.03 (-1.88%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.59%) As of 06/26/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Celularity NASDAQ:CELU$1.91 +0.03 (+1.60%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.52%) As of 06/26/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Clene NASDAQ:CLNN$3.92 -0.18 (-4.39%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$4.21 +0.29 (+7.37%) As of 06/26/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.IMMURON NASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
